Leukocyte Adhesion Deficiency
- Author: Stephen J Nervi, MD; Chief Editor: Harumi Jyonouchi, MD more...
Leukocyte adhesion deficiency (LAD) is a rare primary immunodeficiency.[1, 2] The clinical picture is characterized by marked leukocytosis and localized bacterial infections that are difficult to detect until they have progressed to an extensive level secondary to lack of leukocyte recruitment at the site of infection. Thus the infections in patients with leukocyte adhesion deficiency act similarly as those observed in patients with neutropenia. See the images below.
Leukocyte adhesion deficiency type I (LAD I) is a failure to express CD18, which composes the common ß2 subunit of LFA1 family (ß2 integrins). CD11a/CD18 (LFA-1) expressed on lymphocytes is known to play an important role in lymphocyte trafficking (adhesion to vascular endothelium), as well as interactions to antigen presenting cells (APC). LFA-1 also plays a role of cytotoxic killing by T cells. Another member of this family is CD11bCD18 (MacA or CR3) and CD11cCD18(CR4). These 2 members mediate leukocyte adhesions to endothelial cells but they also serve as receptors for iC3b (inactivated C3b). These patients succumb to life-threatening infection, usually within 2 years of life in severe cases of leukocyte adhesion deficiency I (< 1% expression of CD18). In milder forms of leukocyte adhesion deficiency I (1-30% expression of CD8), patients may survive to adulthood.
Leukocyte adhesion deficiency type II is extremely rare; only a handful cases have been reported and most of them are of Middle Eastern decent. It is a defect in the expression of ligands for selectins due to lack of enzymes required for expression of selectin ligands. Patients have leukocytosis, recurrent infections (more prominent in infants and toddlers), and severe growth and mental retardation. This disease is a defect in fucose metabolism (lack of fucosylation of the carbohydrate selectin ligands) that results in failure to express the ligand for E and P selectin, sialyl Lewis-X (CD15s) expressed on leukocytes and endothelial cells. The patients are unable to fucosylate other glycoproteins, including the H blood group polysaccharide.
Patients with leukocyte adhesion deficiency II manifest the Bombay phenotype (ie, negative for O and H blood group antigens with potential production of anti-H antibody). The immunoglobulin M (IgM) and immunoglobulin G (IgG) heavy chains are also not fucosylated. However, IgM and IgG serum levels are within the reference range in patients with leukocyte adhesion deficiency II.
Leukocyte adhesion deficiency II may be classified as one of the congenital disorders of glycosylation (CDG), a rapidly expanding group of metabolic syndromes with a wide symptomatology and severity. All stem from dysfunctional N -glycosylation of proteins. Currently, 18 subtypes have been reported: 12 are type I (dysfunctional lipid-linked oligosaccharide precursor synthesis), and 6 are type II (dysfunctional trimming/processing of the protein-bound oligosaccharide), including leukocyte adhesion deficiency II (CDG-IIc).
Variants of leukocyte adhesion deficiency have also been reported, including fully expressed but nonfunctional CD18 and an E selectin that is expressed but rapidly cleaved from the cell surface (only present in soluble form). Another reported type of leukocyte adhesion deficiency involves dysfunction in platelet aggregation in addition to a defect in leukocyte adhesion. Thus, patients with this type of leukocyte adhesion deficiency manifest both severe bacterial infections and bleeding disorder. This leukocyte adhesion deficiency variant is associated with defective expression of the Rap-1 activator CalDAG-GEFI. Rap-1 is an essential protein involved in signaling mediated by integrins.
More than one leukocyte adhesion deficiency variant has been labeled leukocyte adhesion deficiency type III (LAD III), creating confusion in the literature.
Peripheral blood leukocytes undergo a sequence of activation that leads to migration of cells into the site of inflammation. First, the cells roll along endothelial surfaces, a process that requires expression of P and E selectins on the endothelial cells and their ligands on leukocytes. Rolling is a reversible process, partly because E selectin is shed from the cell surface and P selectin is internalized in endothelial cells. Next, cells adhere to the endothelial surface and enter the tissues by diapedesis; this process requires the family of integrins. Most importantly, CD18 is the essential component of the ß2 integrins CD11a/CD18, CD11b/CD18, and CD11b/CD18. Ligands of ß2 integrins expressed on endothelial cells belong to the Ig supergene family.
ß2 integrins are heterodimeric glycoproteins that are expressed as transmembrane proteins that transmit signals from the extracellular surface to cytoskeletal proteins. As such, CD18 is an integral part of other phagocytic functions. CD11b/CD18 (Mac-1) on myeloid cells is a receptor for iC3b and, thus, is important for recognizing bacteria and other microorganisms opsonized with iC3b. This recognition leads to phagocytosis and efficient microbicidal activity by the neutrophil, monocyte, or macrophage. Lymphocyte function antigen-1 (LFA-1) or CD11a/CD18, promotes adhesion by its expression on lymphocytes, monocytes, and neutrophils but also plays a role as one of the costimulatory molecules between lymphocyte and APC interactions. The third β2 integrin is CD11c/CD18 (p150/95) and is expressed on myeloid cells and some natural killer cells.
Binding of CD11/CD18 to ligands induces intracellular signaling that activates multiple cellular functions including cytokine production, cytotoxicity, apoptosis, and proliferation.
The major selectin ligand, sialylated Lewis X (SleX), is absent in leukocyte adhesion deficiency II. SleX, or CD15s, is a blood group tetrasaccharide. Both the sialic acid and the fucose moieties of SleX are needed for binding to the selectins; a primary defect in fucosylation in leukocyte adhesion deficiency II results in absence of fucosylated glycans in the cell surface including SleX.
Two other integrins are known to induce adhesion to extracellular proteins such as fibronectin, collagen, and laminin. These are members of the ß1 integrin subfamily, α4ß1, and the α4ß7. Both are expressed on lymphocytes, eosinophils, and natural killer cells.
Irish setter dogs and Holstein cattle have a disorder similar to human leukocyte adhesion deficiency I with leukocytosis and increased infections. This is secondary to a mutation in the gene homologous to human CD18. Both strains serve as promising large-animal models for leukocyte adhesion deficiency.
Knockout mice have been developed with the genes deleted for many of the adhesion-related molecules, (eg, CD18, CD11a, CD11b, ICAM1, ICAM2; E, P, and L selectins; fucosyl transferase; acetylglucosaminyltransferase). The murine models have milder disease than LAD I in humans, and no growth or mental defects as observed in murine leukocyte adhesion deficiency II models; most knockout mice strains revealed mild-to-moderate neutrophilia, but infections are absent except for CD18 knockout mice.
Leukocyte adhesion deficiency I has been reported in fewer than 400 individuals; 75% have the severe form, expressing less than 1% CD18. Only a handful of children have been described with leukocyte adhesion deficiency II. Three cases of with variant leukocyte adhesion deficiency I or decreased cell-expressed E selectin have been reported in the literature.
Although leukocyte adhesion deficiency I is rare, it is reported worldwide, indicating a lack of ethnic predisposition. Patients with leukocyte adhesion deficiency II are mainly reported in the Middle East and Brazil.
Most patients with severe leukocyte adhesion deficiency I succumb to death within the first year of life. Bacterial infections not treated with stem cell transplantation are responsible for most deaths. Life-threatening viral infections are less frequently reported; however, aseptic meningitis and croup-like syndromes are well known complications as described in a 1985 review by Anderson et al.
Patients with leukocyte adhesion deficiency II usually do not succumb to death with infections but develop severe mental retardation and developmental delay, neurologic impairment, and short stature. Periodontitis and colitis in rare occasions may be found in older individuals with leukocyte adhesion deficiency II.
Leukocyte adhesion deficiency I can affect people of all racial groups. Leukocyte adhesion deficiency II has been reported only in people from the Middle East and Brazil.
Approximately equal numbers of males and females are affected, which is consistent with the autosomal recessive inheritance in both leukocyte adhesion deficiency I and leukocyte adhesion deficiency II.
Most patients present within the first several months of life. Delayed umbilical cord separation beyond the normal range of 3-45 days is the classic presentation for leukocyte adhesion deficiency I. Patients who are less severely affected may not be identified until periodontitis develops with tooth eruption; oral ulcerations may be present at the same age. Patients who survive into childhood without hematopoietic stem cell transplantation (HSCT) express some CD18 on leukocytes and have less severe infections.
Patients with leukocyte adhesion deficiency II do not have delayed umbilical cord separation. They may be identified by their characteristic facial appearance and growth failure and, in some cases, by prenatal ultrasonography.
[Guideline] Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005 May. 94(5 Suppl 1):S1-63. [Medline].
Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Ann N Y Acad Sci. 2012 Feb. 1250(1):50-5. [Medline].
Cagdas D, Yilmaz M, Kandemir N, Tezcan I, Etzioni A, Sanal O. A Novel Mutation in Leukocyte Adhesion Deficiency Type II/CDGIIc. J Clin Immunol. 2014 Nov. 34(8):1009-14. [Medline].
Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985 Oct. 152(4):668-89. [Medline].
Helmus Y, Denecke J, Yakubenia S, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. 2006 Feb 2. [Medline].
Alon R, Etzioni A. LAD-III, a novel group of leukocyte integrin activation deficiencies. Trends Immunol. 2003 Oct. 24(10):561-6. [Medline].
Kinashi T, Aker M, Sokolovsky-Eisenberg M, et al. LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds. Blood. 2004 Feb 1. 103(3):1033-6. [Medline]. [Full Text].
McDowall A, Svensson L, Stanley P, Patzak I, Chakravarty P, Howarth K, et al. Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. Blood. 2010 Jun 10. 115(23):4834-42. [Medline].
Lorusso F, Kong D, Jalil AK, et al. Preimplantation genetic diagnosis of leukocyte adhesion deficiency type I. Fertil Steril. 2006 Feb. 85(2):494.e15-8. [Medline].
Elhasid R, Rowe JM. Hematopoetic Stem Cell Transplantation in Neutrophil Disorders: Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency and Chronic Granulomatous Disease. Clin Rev Allergy Immunol. 2009 May 19. [Medline].
Stepensky PY, Wolach B, Gavrieli R, Rousso S, Ben Ami T, Goldman V, et al. Leukocyte Adhesion Deficiency Type III: Clinical Features and Treatment With Stem Cell Transplantation. J Pediatr Hematol Oncol. 2014 Jul 28. [Medline].
Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med. 2014 Mar 26. 6(229):229ra40. [Medline]. [Full Text].
Alon R, Aker M, Feigelson S, et al. A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow. Blood. 2003 Jun 1. 101(11):4437-45. [Medline]. [Full Text].
Bauer TR Jr, Hickstein DD. Gene therapy for leukocyte adhesion deficiency. Curr Opin Mol Ther. 2000 Aug. 2(4):383-8. [Medline].
Bauer TR, Gu YC, Tuschong LM, et al. Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency. Exp Hematol. 2005 Jun. 33(6):706-12. [Medline].
Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol. 2002 Jan. 9(1):30-5. [Medline].
DeLisser HM, Christofidou-Solomidou M, Sun J, et al. Loss of endothelial surface expression of E-selectin in a patient with recurrent infections. Blood. 1999 Aug 1. 94(3):884-94. [Medline].
Eklund EA, Freeze HH. The congenital disorders of glycosylation: a multifaceted group of syndromes. NeuroRx. 2006 Apr. 3(2):254-63. [Medline].
Etzioni A. Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options. Adv Exp Med Biol. 2007. 601:51-60. [Medline].
Etzioni A, Frydman M, Pollack S, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med. 1992 Dec 17. 327(25):1789-92. [Medline].
Etzioni A, Harlan JM. Cell adhesion and leukocyte adhesion defects. Ochs HD, Puck JM, Smith CI, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. Oxford University Press Inc; 1998. 375-88.
Etzioni A, Sturla L, Antonellis A, et al. Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation. Am J Med Genet. 2002 Jun 15. 110(2):131-5. [Medline].
Farinha NJ, Duval M, Wagner E, et al. Unrelated bone marrow transplantation for leukocyte adhesion deficiency. Bone Marrow Transplant. 2002 Dec. 30(12):979-81. [Medline].
Fiorini M, Vermi W, Facchetti F, et al. Defective migration of monocyte-derived dendritic cells in LAD-1 immunodeficiency. J Leukoc Biol. 2002 Oct. 72(4):650-6. [Medline].
Gu YC, Bauer TR Jr, Ackermann MR, et al. The genetic immunodeficiency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, and mice. Comp Med. 2004 Aug. 54(4):363-72. [Medline].
Harris ES, Shigeoka AO, Li W, et al. A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta1 and beta2 integrins. Blood. 2001 Feb 1. 97(3):767-76. [Medline]. [Full Text].
Hidalgo A, Ma S, Peired AJ, Weiss LA, et al. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood. 2003 Mar 1. 101(5):1705-12. [Medline]. [Full Text].
Hixson P, Smith CW, Shurin SB, Tosi MF. Unique CD18 mutations involving a deletion in the extracellular stalk region and a major truncation of the cytoplasmic domain in a patient with leukocyte adhesion deficiency type 1. Blood. 2004 Feb 1. 103(3):1105-13. [Medline]. [Full Text].
Hogg N, Stewart MP, Scarth SL, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest. 1999 Jan. 103(1):97-106. [Medline].
Kurkchubasche AG, Panepinto JA, Tracy TF Jr, et al. Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease. J Pediatr. 2001 Jul. 139(1):141-7. [Medline].
Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001 May. 28(1):69-72. [Medline].
Malawista SE, de Boisfleury Chevance A, et al. Chemotaxis of non-compressed blood polymorphonuclear leukocytes from an adolescent with severe leukocyte adhesion deficiency. Am J Hematol. 2003 Jun. 73(2):115-20. [Medline].
Mancias C, Infante AJ, Kamani NR. Matched unrelated donor bone marrow transplantation in leukocyte adhesion deficiency. Bone Marrow Transplant. 1999 Dec. 24(11):1261-3. [Medline].
Marquardt T, Brune T, Luhn K, et al. Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr. 1999 Jun. 134(6):681-8. [Medline].
Marquardt T, Luhn K, Srikrishna G, et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999 Dec 15. 94(12):3976-85. [Medline].
Pasvolsky R, Feigelson SW, Kilic SS, et al. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets. J Exp Med. 2007 Jul 9. 204(7):1571-82. [Medline].
Roos D, Meischl C, de Boer M, et al. Genetic analysis of patients with leukocyte adhesion deficiency: genomic sequencing reveals otherwise undetectable mutations. Exp Hematol. 2002 Mar. 30(3):252-61. [Medline].
Shaw JM, Al-Shamkhani A, Boxer LA, et al. Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA-1, Mac-1 and p150,95. Clin Exp Immunol. 2001 Nov. 126(2):311-8. [Medline].
Sturla L, Fruscione F, Noda K, et al. Core fucosylation of N-linked glycans in leukocyte adhesion deficiency/congenital disorder of glycosylation IIc fibroblasts. Glycobiology. 2005 Oct. 15(10):924-34. [Medline].
Sturla L, Rampal R, Haltiwanger RS, et al. Differential terminal fucosylation of N-linked glycans versus protein O-fucosylation in leukocyte adhesion deficiency type II (CDG IIc). J Biol Chem. 2003 Jul 18. 278(29):26727-33. [Medline]. [Full Text].
Uzel G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology. 2001 Oct. 121(4):958-64. [Medline].
Uzel G, Tng E, Rosenzweig SD, Hsu AP, Shaw JM, Horwitz ME. Reversion mutations in patients with leukocyte adhesion deficiency type I (LAD-I). Blood. 2007 Sep 17. [Medline].
Wild MK, Luhn K, Marquardt T, Vestweber D. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs. 2002. 172(3):161-73. [Medline].